SCHEMBL15412942

SCHEMBL15412942

CCCCCCCCNc1ccc(C(=O)OCCN(C)C)cc1

nearest known ligand 0.90

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.90
SCN5A Q14524 2/20 0.90
CYP1A2 P05177 2/20 0.90
MAPK1 P28482 2/20 0.90
MAOA P21397 1/20 0.90
CNR1 P21554 1/20 0.90
DRD4 P21917 1/20 0.90
ACHE P22303 1/20 0.90
HRH2 P25021 1/20 0.90
HTR2A P28223 1/20 0.90
HTR2C P28335 1/20 0.90
NTSR1 P30989 1/20 0.90
HRH1 P35367 1/20 0.90
DRD3 P35462 1/20 0.90
SCN1A P35498 1/20 0.90
HTR2B P41595 1/20 0.90
SCN7A Q01118 1/20 0.90
SLC6A3 Q01959 1/20 0.90
KCNH2 Q12809 1/20 0.90
SCN9A Q15858 1/20 0.90

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetracaine SCHEMBL34714 0.95 LMNA (1.00) LMNASCN5ACYP1A2MAPK1MAOA
Tetracaine SCHEMBL1355595 0.94 LMNA (1.00) LMNASCN5ACYP1A2MAPK1MAOA
Tetracaine SCHEMBL3176478 0.94 LMNA (0.97) LMNASCN5ACYP1A2MAPK1MAOA
Tetracaine SCHEMBL7774179 0.94 LMNA (0.97) LMNASCN5ACYP1A2MAPK1MAOA
Tetracaine SCHEMBL27896875 0.94 LMNA (0.97) LMNASCN5ACYP1A2MAPK1MAOA
Tetracaine SCHEMBL28641231 0.94 LMNA (0.97) LMNASCN5ACYP1A2MAPK1MAOA
Tetracaine SCHEMBL24370 0.94 LMNA (1.00) LMNASCN5ACYP1A2MAPK1MAOA
Tetracaine SCHEMBL1652724 0.92 LMNA (0.95) LMNASCN5ACYP1A2MAPK1MAOA
Tetracaine SCHEMBL2728732 0.92 LMNA (0.95) LMNASCN5ACYP1A2MAPK1MAOA
Tetracaine SCHEMBL1840446 0.90 LMNA (0.90) LMNASCN5ACYP1A2MAPK1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9458102-B2 Derivatives of tetracaine OREGON HEALTH & SCIENCE UNIVERSITY (US) 2016-10-04 US disclosed
US-9458102-B2 Derivatives of tetracaine OREGON HEALTH & SCIENCE UNIVERSITY (US) 2016-10-04 US disclosed
US-9458102-B2 Derivatives of tetracaine OREGON HEALTH & SCIENCE UNIVERSITY (US) 2016-10-04 US disclosed
US-20140018422-A1 DERIVATIVES OF TETRACAINE WILLAMETTE UNIVERSITY (US) 2014-01-16 US disclosed
US-20140018422-A1 DERIVATIVES OF TETRACAINE WILLAMETTE UNIVERSITY (US) 2014-01-16 US disclosed
US-20140018422-A1 DERIVATIVES OF TETRACAINE WILLAMETTE UNIVERSITY (US) 2014-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018422-A1 DERIVATIVES OF TETRACAINE CACNA1G, CACNA1H, CACNA1I LMNA 3105/4885SCN5A 137/4885CYP1A2 4272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.